View source for CT-868

{{Orphan|date=December 2023}}
'''CT-868''' is an experimental "biased dual  [[GLP-1]] and [[GIP receptor]] modulator that exhibits no [[arrestin]] coupling or [[receptor internalization]] at either receptor". It is developed by Carmot Therapeutics for diabetes and obesity.<ref>{{cite journal |last1=Chakravarthy |first1=Manu |last2=Hernandez |first2=Moises |last3=Elliott |first3=Michael |last4=Macias |first4=Alejandra |last5=Hansen |first5=Stig K. |last6=Hompesch |first6=Marcus |title=774-P: Weight-Independent Effects of CT-868, a Signaling Biased Dual GLP-1/GIP Receptor Modulator, on Glucose Homeostasis in Overweight and Obese Adults with Type 2 Diabetes |journal=Diabetes |date=20 June 2023 |volume=72 |issue=Supplement_1 |doi=10.2337/db23-774-P|s2cid=259219222 }}</ref><ref>{{cite journal |last1=Rodriguez |first1=Ruben |last2=Tracy |first2=Ted |last3=Morales |first3=Marikris |last4=Hergarden |first4=Anne |last5=Lam |first5=Davina |last6=Krishnan |first6=Shyam |last7=Hansen |first7=Stig K. |last8=Chakravarthy |first8=Manu |title=1649-P: Biased GLP-1 Improves Weight Loss with Additional Benefits on Glucose Homeostasis via Biased GIP in Diabetic Rodent Models |journal=Diabetes |date=20 June 2023 |volume=72 |issue=Supplement_1 |doi=10.2337/db23-1649-P|s2cid=259427049 }}</ref>
==References==
{{reflist}}
[[Category:GLP-1 receptor agonists]]
[[Category:GIP receptor agonists]]